Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348904 · ClinicalTrials.gov registry record · Phase 3
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT03348904 is a Phase 3 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 2 participants.
The verdict
NCT03348904, a Phase 3 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Cisplatin
- DRUG Epacadostat
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03348904
The ClinicalTrials.gov registry entry for NCT03348904 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03348904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03348904 about?
NCT03348904 is a clinical study titled "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer". The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).
What is the current status of trial NCT03348904?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2017-12-27. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT03348904?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Cisplatin (DRUG), Epacadostat (DRUG), Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03348904?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.